ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO903

Vaccination Reduces Risk of CKD Associated With COVID-19 Disease

Session Information

  • COVID-19: Long COVID
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Mir, Hamza, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
  • Roumelioti, Maria-Eleni, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
  • Argyropoulos, Christos, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

COVID19 disease has emerged as a major risk factor of chronic health conditions, i.e. PostAcute Sequelae of COVID19 (PASC). With the emergence of more transmissible variants , the global human population will eventually be exposed to the spike protein of SARS-COV-2 either through natural infection or vaccination. It remains unknown whether vaccination may affect the kidney manifestations of PASC.


We searched TrinetX, a large health research network that aggregates data from multiple centers in the United States to analyze the effects of vaccination on CKD manifestations of PASC. We classified patients as C19+ve (with a [+] molecular test for SARS-COV-2 or a clinical diagnosis of COVID19 disease) and Vax7+ve if they had at least one dose of any COVID19 vaccine and did not have a breakthrough infection. We collected demographics, comorbidities, diagnoses for up to 2 years after any COVID19 PCR test (index event). A 1:1 propensity score matching (PSM) using the nearest neighbor method was used to balance the two cohorts on age, gender, Hispanic ethnicity, black race, hypertension, diabetes, heart failure and atherosclerosis. Patients with a kidney specific diagnosis prior to their COVID19 PCR test were excluded.


We identified 2,780,576 C19+ve and 735,966 Vax+ve patients. After PSM each group contained 736,034 subjects. Mean age was 51.5±21.4, females were 58.8%, blacks were 14.9% & 9.9% were Hispanic or Latinos. COVID19 vaccination was associated with reduced risk of incident CKD, unspecified kidney failure and the nephritic syndrome, but did not reduce the risk of the nephrotic syndrome or glomerulonephritis relative to COVID19 disease.


Vaccination may reduce the risk of CKD associated with PASC. If confirmed in a prospective study, our findings can expand the known benefits of vaccination on the acute disease to PASC manifestations, potentially improving the uptake of the COVID19 vaccines by the population.

Incident Kidney Specific Diagnosis
Diagnosis (ICD10)Vax+veC19+veRR95%CI
CKD (N18)16,456/670,26629,158/632,6830.533(0.523, 0.543)
Unspecified kidney failure (N19)1,409/730,1505,268/724,6750.265(0.250, 0.282)
Nephritic syndrome (N05)573/732,497673/733,0190.852(0.762, 0.952)
Nephrotic Syndrome (N04)403/734,394351/734,5001.148(0.995, 1.325)
Glomerular disease (N00-N08)1,354/727,9171,298/729,0781.045(0.968, 1.127)